GoodRx is a consumer-facing digital platform that helps Americans find discounted prices on prescription medications. Consumers search for a drug on GoodRx's app or website, see real-time prices at nearby pharmacies, and present a GoodRx code at the pharmacy counter to pay a discounted cash price — often below their insurance co-pay. GoodRx aggregates pricing data from pharmacy benefit managers (PBMs) and direct pharmacy contracts into a single interface, covering 70,000+ pharmacy locations nationwide. The platform serves both insured and uninsured consumers, with over 25 million consumers using it annually. GoodRx generates revenue through three offerings: prescription transactions (~68% of revenue), where GoodRx earns a fee from PBMs or pharmacies each time a consumer fills a prescription using a GoodRx code; Pharma Direct (~19%), where GoodRx charges pharmaceutical manufacturers to promote affordability programs and direct cash-pay pricing to high-intent consumers already searching for their drugs; and subscriptions (~11%), including its Gold membership and newer condition-specific bundles that package a telehealth visit, prescription, and home delivery for conditions like weight loss and erectile dysfunction. GoodRx is actively shifting its growth focus toward Pharma Direct and condition-specific subscriptions, while managing the core prescription marketplace for stability. The core prescription transactions business is volume-driven and high-margin, while Pharma Direct is more recurring and growing faster. GoodRx's key structural risk is its reliance on a small number of PBMs for a significant share of prescription transaction revenue.
Read full business overview →Mid to long-term bullish thesis
View →Mid to long-term bearish thesis
View →Mid to long-term bull-bear debate
View → NEWSummary and scoring of the bull-bear debate
View →Find ideas with similar bull or bear theses
View →Investor-relevant company attributes
View →Key risks to the business
View →Comparisons of annual risk disclosures
View →